Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer: Final Results of the VICTOR Trial
- 20 October 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (30) , 4575-4580
- https://doi.org/10.1200/jco.2010.29.6244
Abstract
Purpose Laboratory and case-control studies suggest a pivotal role for the cyclooxygenase-2 (COX-2) pathway in colorectal carcinogenesis. The purpose of this study was to test whether the COX-2 inh...Keywords
This publication has 25 references indexed in Scilit:
- Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised studyThe Lancet, 2007
- Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2New England Journal of Medicine, 2007
- Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized TrialsJournal of Clinical Oncology, 2005
- A Molecular/Epidemiologic Analysis of Expression of Cyclooxygenases 1 and 2,Use of Nonsteroidal Antiinflammatory Drugs, and Risk of Colorectal AdenomaClinical Colorectal Cancer, 2005
- Expression of cyclooxygenase-2 in colorectal cancer and its clinical significanceWorld Journal of Gastroenterology, 2005
- Cyclooxygenase-2 ExpressionClinical Cancer Research, 2004
- The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastasesPublished by Elsevier ,2003
- Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trialThe Lancet, 2000
- Towards post-genomic investigation of colorectal cancerThe Lancet, 2000
- The Relationship Between Cyclooxygenase-2 Expression and Colorectal CancerJAMA, 1999